Natural history of gastroesophageal reflux disease and functional abdominal disorders: A population-based study

American Journal of Gastroenterology

Volumn 96, Issue 10, 2001, Pages 2905-2914

  Agréus, Lars ^a,c   Svärdsudd, Kurt ^b   Talley, Nicholas J ^d   Jones, Michael P ^e   Tibblin, Gösta ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Primary Health Care Centre   (Sweden)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Jones and Just   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL DISEASE; ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SWEDEN;

ADULT; AGED; CHRONIC DISEASE; COLONIC DISEASES, FUNCTIONAL; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; REGRESSION ANALYSIS;

EID: 0034793941     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03242-7     Document Type: Article

References (72)

1. Dyspepsia in England and Scotland
2. The epidemiology of abdominal symptoms: Prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study
3. Dyspepsia and dyspepsia subgroups: A population-based study
4. Identification of upper and lower gastrointestinal symptom groupings in an urban population
5. Symptomatic gastroesophageal reflux: Incidence and precipitating factors
6. Manometric oesophageal function, acid perfusion test and symptomatology in a 55-year-old general population
7. Heartburn and globus in apparently healthy people
8. The prevalence of symptoms suggestive of esophageal disorders
9. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota
10. Mave-tarmsymptomer blandt 40-årige i Glostrup. En epidemiologisk undersøgelse
11. Peptic ulcer and non-ulcer dyspepsia - A disease and a disorder
12. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time
13. Irritable bowel syndrome in the general population
14. Irritable bowel syndrome in a community: Symptom subgroups, risk factors, and health care utilization
15. Economic costs of functional dyspepsia
16. Medical costs in community subjects with irritable bowel syndrome
17. Dyspepsia in the community: A follow-up study
18. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact
19. Socio-economic factors, health care consumption and rating of abdominal symptom severity. A report from the abdominal symptom study
20. Dyspepsia in consulters and non-consulters: Prevalence, health-care seeking behaviour and risk factors
21. Predictors of health care seeking for irritable bowel syndrome: A population based study
22. The diagnosis and therapy survey, October-March 1983, health care consumption and current drug therapy in Sweden with respect to the clinical diagnosis of gastritis
23. Clinical economics review: Gastrointestinal disease in primary care
24. Prescribing patterns for dyspepsia in primary care: A prospective study of selected general practitioners
25. Functional dyspepsia: A classification with guidelines for diagnoses and management
26. Geographical differences in the prevalence of dyspepsia
27. The "epigastric distress syndrome." A possible disease entity identified by history and endoscopy in patients with nonulcer dyspepsia
28. Controlled treatment trials in the irritable bowel syndrome: A critique
29. Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials
30. Natural history of reflux oesophagitis: A 10 year follow up of its effect on patient symptomatology and quality of life
31. Non-ulcer dyspepsia in the long-term perspective
32. The irritable colon syndrome: A study of the clinical features, predisposing causes, and prognosis in 139 cases
33. The irritable bowel syndrome: Long-term prognosis and the physician-patient interaction
34. Reproducibility and validity of a postal questionnaire. The abdominal symptom study
35. Identifying dyspepsia and irritable bowel syndrome: The value of pain or discomfort, and bowel habit descriptors
36. Symptoms in gastro-oesophageal reflux disease
37. AGA technical review: Evaluation of dyspepsia
38. Functional gastroduodenal disorders: A working team report for the ROME II consensus on functional gastrointestinal disorders
39. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population
40. Vad händer med esofagala symptom med tiden?
41. Importance of reflux symptoms in functional dyspepsia
42. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: Six year follow up of 107 patients
43. Management of dyspepsia: Report of a working party
44. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
45. A study of caffeine consumption and symptoms; indigestion, palpitations, tremor, headache and insomnia
46. Introduction to the epidemiology of dyspepsia
47. Functional bowel disorders in apparently healthy people
48. Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters
49. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction
50. Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: A four nations study
51. Evidence that the irritable bowel syndrome and functional dyspepsia are single disorders: A population based study
52. An evidence-based appraisal of reflux disease management. The Genval Workshop Report
53. Is it possible to simplify the definition of the irritable bowel syndrome in population-based studies and clinical practice?
54. Kruis scoring system and Manning's criteria in diagnosis of irritable bowel syndrome: Is it better to use combined?
55. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice
56. The management of acid-related dyspepsia in general practice: A comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy
57. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response
58. A qualitative study of medication-taking behaviour in primary care
59. Towards a true prevalence of peptic ulcer: The Sørreisa gastrointestinal disorder study
60. A review of peptic ulceration in coroners' autopsies
61. Helicobacter pylori seropositivity among Swedish adults with and without abdominal symptoms. A population-based epidemiologic study
62. Endomysium antibodies are superior to gliadin antibodies in screening for coeliac disease in patients presenting supposed functional gastrointestinal symptoms
63. Studies of the epidemiology of peptic ulcer in a rural community: Prevalence and natural history of dyspepsia and peptic ulcer
64. Upper dyspepsia among 30 to 60 years-old - Five year follow-up in a population study
65. Recurrent abdominal pain: A potential precursor of irritable bowel syndrome in adolescents and young adults